CIK 0001321834 · Non-accelerated filer<br>Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-14 | Bernstein Bruce Director | Grant or award | +25,000 | 25,000 | ||
| 2025-11-14 | RAUCH GARY M Vice President of Finance | Grant or award | +11,420 | 12,500 | ||
| 2025-10-03 | White Billy Joe Director | Grant or award | +2,161 | 2,185 | ||
| 2025-10-03 | Silverman Joshua Executive Chairman | Grant or award | +8,644 | 8,673 | ||
| 2025-10-03 | RAUCH GARY M Vice President of Finance | Grant or award | +1,080 | 1,080 | ||
| 2025-10-03 | Glass Mitchell Director, Chief Medical Off. | Grant or award | +1,080 | 1,080 | ||
| 2025-10-03 | Friscia Stephen Director | Grant or award | +2,161 | 2,161 | ||
| 2025-09-04 | PharmaCyte Biotech, Inc. 10% owner | Purchase · Series H Convertible Preferred Stock | +889,865 | 889,865 | ||
| 2025-04-17 | RHODES IAN Interim CFO | Grant or award · Employee Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-04-17 | RAUCH GARY M Vice President, Finance | Grant or award · Employee Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2025-04-17 | Glass Mitchell President, CMO | Grant or award · Employee Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2023-08-24 | Rivard Paul Chief Legal Officer | Purchase | +150,000 | $1.11 | $167K | 400,000 |
| 2023-08-17 | Rivard Paul Chief Legal Officer | Purchase | +25,000 | $1.12 | $28K | 250,000 |
| 2023-06-07 | Rivard Paul Chief Legal Officer | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-06-07 | Uzonwanne Jude Director | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-06-07 | Silverman Joshua Director | Grant or award · Employee Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-06-07 | EAGLE CRAIG Director | Grant or award · Employee Stock Option (Right to Buy) | +475,000 | 475,000 | ||
| 2023-06-07 | Schreiber Christopher C Director | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-06-07 | Chapman Christopher C JR President, Chief Med. Officer | Grant or award · Employee Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2023-06-07 | White Billy Joe Director | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 |
Page 2 of 8 · 142 trades